Defects in Fas-mediated apoptosis are implicated in autoimmune diseases including rheumatoid arthritis (RA). Although induction of Fas-mediated apoptosis could have therapeutic effects on these diseases, it might cause deleterious effects in liver as Fas ligand or an agonistic anti-murine Fas antibody Jo2 causes severe hepatic injury in mice. We report here on the interesting characteristics of the newly obtained anti-Fas mAb, HFE7A, which cross-reacts with the Fas molecules of various species ranging from human to mouse and mitigates autoimmune symptoms without hepatotoxicity in mice. The administration of HFE7A to mice induced apoptosis in the thymocytes, although administration of HFE7A to mice or to marmosets did not induce any sign of hepatitis. The effect of HFE7A on liver is different from that of anti-murine Fas antibody Jo2, which causes acute and lethal hepatic injury to mice. Administration of HFE7A reduced lymphadenopathy and abnormal T cells in MRL-gld/gld mice. HFE7A induced apoptosis in synovial cells prepared from RA patients. Surprisingly, HFE7A protected mice from fulminant hepatitis induced by Jo2. Therefore, HFE7A is a potential therapeutic antibody not only for autoimmune diseases including RA but also for fulminant hepatitis.
Apoptosis, or programmed cell death, is involved in many biological processes including embryogenesis, development of the immune system, elimination of virus-infected cells, and maintenance of tissue homeostasis.1) Binding of Fas ligand (FasL) to Fas induces apoptosis. Fas is a type-I membrane protein and belongs to the tumor necrosis factor (TNF) receptor family.2,3) FasL, a member of the TNF family, is synthesized as a type-II membrane protein and digested proteolytically to a soluble form. 4,5) Mice with mutations of Fas and/or FasL develop massive lymphadenopathy and autoimmune diseases, which indicates that the Fas-FasL system plays an important role in the elimination of autoreactive lymphoid cells. 6)The mouse monoclonal antibody HFE7A (m-HFE7A), raised against human Fas, binds to both human and mouse Fas. 7,8) Administration of m-HFE7A to mice induces apoptosis in thymocytes. However, in mice, m-HFE7A shows no sign of the hepatotoxicity observed with the hamster antimurine Fas monoclonal antibody Jo2. 9) Moreover, administration of m-HFE7A to mice prevents the injury of the liver induced by Jo2. Therefore, m-HFE7A may provide a useful treatment for autoimmune diseases such as rheumatoid arthritis and fulminant hepatitis.A major limitation in the use of murine antibodies for human therapy is the human anti-mouse antibody response, resulting in potentially harmful reactions and the rapid clearance of circulating antibody. 10,11) To reduce the immunogenicity of murine antibodies for human therapy, chimeric antibodies were initially developed.12) Chimeric antibodies consist of the mouse variable domains and the human constant domains. Even chimeric antibodies are still capable of eliciting a significant immune response.13) An approach to overcome the limitation in the clinical use of murine antibodies is humanization of murine antibodies.14) This technique involves transplantation of the murine residues in the complementarity-determining regions (CDRs), which are important for antigen binding, into a relevant human antibody. However, direct grafting of only the CDR residues has sometimes decreased the binding affinity. 15,16) Therefore, in addition to the CDR residues, some murine residues at the key positions in the framework region must also be incorporated into the human framework to maintain the proper CDR conformation. For this process, information on the three-dimensional structure is essential to minimize the number of murine residues to be transferred and avoid the human antimouse antibody response.In this report, we describe humanization of m-HFE7A by the CDR grafting method for the treatment of the human diseases. Five versions of humanized HFE7A (h-HFE7A) induced the same degree of apoptosis in WR19L12a cells as chimeric HFE7A (chi-HFE7A) does. To further probe the structural basis on antibody humanization, we selected one of five h-HFE7As, h-HFE7A-d, since the d version has the smallest number of residues transferred from m-HFE7A among five h-HFE7As and determined the crystal structure of the h-H...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.